Payment overview · 2025
General Payments
$4,459.53
218 reported records · 19 companies
Healthcare provider profile · identity verified
Jonathan George Tardos, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · SOMERSET, NJ · NPI 1235391038
Verified facts
What the public records show
CMS Open Payments records show Jonathan George Tardos, MD received $4,459.53 in general payments during 2025 across 218 reported records.
Medtronic, Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 496 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,875.30 | 42.0% | 49 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $662.73 | 14.9% | 34 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $511.98 | 11.5% | 38 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $249.13 | 5.6% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $221.43 | 5.0% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.21 | 4.6% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $182.81 | 4.1% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $106.03 | 2.4% | 6 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.54 | 1.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.11 | 1.9% | 5 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $78.29 | 1.8% | 3 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $37.00 | 0.8% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $32.53 | 0.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.60 | 0.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $31.30 | 0.7% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.34 | 0.4% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $18.54 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.13 | 0.3% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,483.54 | 213 |
| Travel and Lodging | $975.99 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $1,490.46 | 13 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $351.10 | 31 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $266.87 | 9 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $249.40 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $249.13 | 16 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $221.75 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $182.81 | 17 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $151.87 | 13 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $122.98 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $106.03 | 6 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $98.45 | 8 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $88.96 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $78.76 | 8 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $78.29 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.54 | 4 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $58.86 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.34 | 4 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $37.00 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $36.85 | 4 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| SPHERE-9 Normalized: sphere 9 |
Device | Medtronic, Inc. | $21.66 | 3 | 2025 |
Source payment records
|
|||||
| ADVISOR Normalized: advisor |
Device | Abbott Laboratories | $20.88 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $18.20 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| AGILIS Normalized: agilis |
Device | Abbott Laboratories | $15.14 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Abbott Laboratories | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $13.65 | 2 | 2025 |
Source payment records
|
|||||
| AMPERE Normalized: ampere |
Device | Abbott Laboratories | $12.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.20 | 1 | 2025 |
Source payment records
|
|||||
| SWARTZ Normalized: swartz |
Device | Abbott Laboratories | $10.10 | 1 | 2025 |
Source payment records
|
|||||
| LIVEWIRE Normalized: livewire |
Device | Abbott Laboratories | $9.47 | 1 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $8.72 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $6.38 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $5.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 496 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 79 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
496 | 161 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 496 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 190 |
| Carvedilol | Carvedilol | 400 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 101 |
| Lisinopril | Lisinopril | 277 | 100 |
| Xarelto | Rivaroxaban | 198 | 54 |
| Furosemide | Furosemide | 193 | 87 |
| Losartan Potassium | Losartan Potassium | 179 | 72 |
| Nifedipine Er | Nifedipine | 166 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 56 |
| Spironolactone | Spironolactone | 123 | 50 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 107 | 44 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 105 | 45 |
| Propranolol Hcl Er | Propranolol Hcl | 105 | 47 |
| Valsartan | Valsartan | 92 | 35 |
| Repatha Sureclick | Evolocumab | 88 | 22 |
| Farxiga | Dapagliflozin Propanediol | 87 | 28 |
| Entresto | Sacubitril/Valsartan | 79 | 30 |
| Jardiance | Empagliflozin | 76 | 16 |
| Simvastatin | Simvastatin | 74 | 27 |
| Warfarin Sodium | Warfarin Sodium | 68 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 31 |
| Fenofibrate | Fenofibrate | 56 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 17 |
| Ezetimibe | Ezetimibe | 49 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 14 |
| Ramipril | Ramipril | 45 | 16 |
| Torsemide | Torsemide | 40 | 21 |
| Flecainide Acetate | Flecainide Acetate | 38 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 20 |
| Midodrine Hcl | Midodrine Hcl | 36 | 18 |
| Chlorthalidone | Chlorthalidone | 31 | 14 |
| Enalapril Maleate | Enalapril Maleate | 31 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 13 |
| Propranolol Hcl | Propranolol Hcl | 29 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | 15 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Atenolol | Atenolol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,459.53 · 218 records | Medtronic, Inc. | ADVISOR, AFFERA MAPPING SYSTEM, AGILIS, AMPERE, AMVIA EDGE, AMVUTTRA, ASSURITY, AVEIR, AZURE XT DR MRI SURESCAN, Acticor 7 VR-T DX, BIOMONITOR, CAPVAXIVE, CARDIOMEMS, Cleerly Ischemia, Cleerly Labs, ELIQUIS, ENSITE, ENSITE PRECISION, ENTRESTO, FARXIGA, FFRct, Flexitouch Plus, GALLANT, Hillrom - Carnation Ambulatory Monitor, JARDIANCE, Kerendia, LEQVIO, LIVEWIRE, LUX-Dx Insertable Cardiac Monitor, MICRA, NA, Nimbl, ONPATTRO, Optimizer, Ozempic, PULSESELECT, RHYTHM EXPRESS, Rybelsus, SPHERE-9, SWARTZ, TACTICATH ABLATION CATHETER, SENSOR ENABLED, TELEPATCH CARDIAC MONITOR, VERQUVO, VYNDAQEL, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error